Nasdaq · CIK 0002042347
SPTX Seaport Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 24, 2026. Close $18.15 on Oct 9, 2026, +19% from the 52-week low and -35% from the high.
In brief
Seaport Therapeutics, Inc. (SPTX) has 15 SEC Form 4 filings on file from 14 insiders, the latest filed on Jun 24, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at SPTX. The newest: Robert J. Hombach (director) bought $236k of stock on Jun 22, 2026, filed Jun 24, 2026, scored 36 (weak). The largest of the 2 shown: ARCH Venture Partners XII, LLC (10% owner) bought $20M on May 4, 2026, scored 38 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Seaport Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Robert J. Hombach director buy | $236k 13,000 shares | - | +18% from low-9% from high | |
| 38Weak | ARCH Venture Partners XII, LLC owner buy | $20M 1,100,000 shares | +21% | - |
Transactions
Every row filed, 41 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Robert J. Hombach director | POpen-market purchase Common Stockindirect: By Robert Joseph Hombach Revocable Trust | +13,000 | $18.14 | $236k | 13,000 | Jun 24, 2026 |
| May 4, 2026 | PureTech Health plc owner | CConversion Common Stockindirect: See footnote | +12,736,014 | - | - | 13,038,493 | May 6, 2026 |
| May 4, 2026 | PureTech Health plc owner | CConversion Common Stockindirect: See footnote | +2,681,265 | - | - | 15,719,758 | May 6, 2026 |
| May 4, 2026 | PureTech Health plc owner | CConversion Common Stockindirect: See footnote | +965,255 | - | - | 16,685,013 | May 6, 2026 |
| May 4, 2026 | PureTech Health plc owner | CConversion Series A-1 Preferred Stockderivativeindirect: See footnote | -40,000,000 | $0.00 | $0 | 0 | May 6, 2026 |
| May 4, 2026 | PureTech Health plc owner | CConversion Series A-2 Preferred Stockderivativeindirect: See footnote | -8,421,052 | $0.00 | $0 | 0 | May 6, 2026 |
| May 4, 2026 | PureTech Health plc owner | CConversion Series B Preferred Stockderivativeindirect: See footnote | -3,031,578 | $0.00 | $0 | 0 | May 6, 2026 |
| May 4, 2026 | ARCH Venture Partners XII, LLC owner | CConversion Common Stockindirect: By ARCH Venture Fund XII, L.P. | +2,513,686 | - | - | 2,513,686 | May 4, 2026 |
| Apr 30, 2026 | Daphne Zohar Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +271,813 | $0.00 | $0 | 271,813 | May 4, 2026 |
| Apr 30, 2026 | David E. Wheadon director | AGrant or award Stock Option (Right to Buy)derivative | +12,258 | $0.00 | $0 | 12,258 | May 4, 2026 |
| Apr 30, 2026 | Sandra E Peterson director | AGrant or award Stock Option (Right to Buy)derivative | +12,258 | $0.00 | $0 | 12,258 | May 4, 2026 |
| Apr 30, 2026 | Sharon Mates director | AGrant or award Stock Option (Right to Buy)derivative | +49,033 | $0.00 | $0 | 49,033 | May 4, 2026 |
| Apr 30, 2026 | Robert J. Hombach director | AGrant or award Stock Option (Right to Buy)derivative | +12,258 | $0.00 | $0 | 12,258 | May 4, 2026 |
| May 4, 2026 | Lauren White Chief Financial Officer | CConversion Common Stockindirect: By Lauren Anne White Living Trust, dated January 30, 2020 | +6,702 | - | - | 6,702 | May 4, 2026 |
| May 4, 2026 | Denice Torres director | CConversion Common Stockindirect: By Denice M. Torres Revocable Trust | +13,406 | - | - | 13,406 | May 4, 2026 |
| May 4, 2026 | Steven M Paul director | CConversion Common Stock | +67,031 | - | - | 863,031 | May 4, 2026 |
| May 4, 2026 | Antony Loebel Chief Medical Officer | CConversion Common Stock | +20,109 | - | - | 20,109 | May 4, 2026 |
| May 4, 2026 | James Healy director | CConversion Common Stockindirect: By Sofinnova Venture Partners XI, L.P. | +1,927,159 | - | - | 1,927,159 | May 4, 2026 |
| May 4, 2026 | Lana Gladstein General Counsel | CConversion Common Stock | +33,515 | - | - | 33,515 | May 4, 2026 |
| May 4, 2026 | Michael Cunyuan Chen Chief Scientific Officer | CConversion Common Stock | +3,351 | - | - | 3,351 | May 4, 2026 |
| Apr 30, 2026 | Michael Cunyuan Chen Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +63,680 | $0.00 | $0 | 63,680 | May 4, 2026 |
| Apr 30, 2026 | Daphne Zohar Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,486,786 | $0.00 | $0 | 1,486,786 | May 4, 2026 |
| May 4, 2026 | ARCH Venture Partners XII, LLC owner | CConversion Common Stockindirect: By ARCH Venture Fund XII, L.P. | +2,681,265 | - | - | 5,194,951 | May 4, 2026 |
| Apr 30, 2026 | Lauren White Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +63,680 | $0.00 | $0 | 63,680 | May 4, 2026 |
| Apr 30, 2026 | Denice Torres director | AGrant or award Stock Option (Right to Buy)derivative | +12,258 | $0.00 | $0 | 12,258 | May 4, 2026 |
| Apr 30, 2026 | Steven M Paul director | AGrant or award Stock Option (Right to Buy)derivative | +12,258 | $0.00 | $0 | 12,258 | May 4, 2026 |
| Apr 30, 2026 | Antony Loebel Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +63,680 | $0.00 | $0 | 63,680 | May 4, 2026 |
| Apr 30, 2026 | Lana Gladstein General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +63,680 | $0.00 | $0 | 63,680 | May 4, 2026 |
| May 4, 2026 | James Healy director | CConversion Common Stockindirect: By Sofinnova Venture Partners XI, L.P. | +804,379 | - | - | 2,731,538 | May 4, 2026 |
| May 4, 2026 | Antony Loebel Chief Medical Officer | CConversion Series B Preferred Stockderivative | -63,157 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | Lauren White Chief Financial Officer | CConversion Series B Preferred Stockderivativeindirect: By Lauren Anne White Living Trust, dated January 30, 2020 | -21,052 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | Michael Cunyuan Chen Chief Scientific Officer | CConversion Series B Preferred Stockderivative | -10,526 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | Denice Torres director | CConversion Series B Preferred Stockderivativeindirect: By Denice M. Torres Revocable Trust | -42,105 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | Lana Gladstein General Counsel | CConversion Series B Preferred Stockderivative | -105,263 | $0.00 | $0 | 0 | May 4, 2026 |
| Apr 30, 2026 | Steven M Paul director | AGrant or award Stock Option (Right to Buy)derivative | +991,192 | $0.00 | $0 | 991,192 | May 4, 2026 |
| May 4, 2026 | ARCH Venture Partners XII, LLC owner | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XII, L.P. | +1,100,000 | $18.00 | $20M | 6,294,951 | May 4, 2026 |
| May 4, 2026 | James Healy director | CConversion Series A-2 Preferred Stockderivativeindirect: By Sofinnova Venture Partners XI, L.P. | -6,052,631 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | ARCH Venture Partners XII, LLC owner | CConversion Series A-2 Preferred Stockderivativeindirect: By ARCH Venture Fund XII, L.P. | -2,513,686 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | James Healy director | CConversion Series B Preferred Stockderivativeindirect: By Sofinnova Venture Partners XI, L.P. | -2,526,315 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | Steven M Paul director | CConversion Series B Preferred Stockderivative | -210,526 | $0.00 | $0 | 0 | May 4, 2026 |
| May 4, 2026 | ARCH Venture Partners XII, LLC owner | CConversion Series B Preferred Stockderivativeindirect: By ARCH Venture Fund XII, L.P. | -2,681,265 | $0.00 | $0 | 0 | May 4, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- ARCH Venture Partners XII, LLCowner, director
- Michael Cunyuan ChenChief Scientific Officer
- Lana GladsteinGeneral Counsel
- James Healydirector
- Robert J. Hombachdirector
- Antony LoebelChief Medical Officer
- Sharon Matesceo, chair, officer, director, president
- Steven M Pauldirector
- Sandra E Petersondirector
- PureTech Health plcowner
- Denice Torresdirector
- David E. Wheadondirector
- Lauren WhiteChief Financial Officer
- Daphne ZoharChief Executive Officer
Questions about SPTX
Answered from the filings on this page, as of the latest one.
Are insiders buying SPTX?
No. In the last 90 days no insider at Seaport Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SPTX on the open market?
Robert J. Hombach (director) bought $236k of SPTX on Jun 22, 2026 and filed the Form 4 on Jun 24, 2026. InsiderTell scored 36 (weak).
How many insiders file Form 4 at Seaport Therapeutics, Inc.?
14 people have filed a Form 4 at Seaport Therapeutics, Inc., among them ARCH Venture Partners XII, LLC (10% owner and director), Michael Cunyuan Chen (Chief Scientific Officer), Lana Gladstein (General Counsel). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.